Auf dieser Seite
JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
NASDAQ · Pharmaceuticals · Auf SEC EDGAR ansehen ↗ Schließen Okt 5, 2026 10-K/10-Q Aug 3, 2026
$236,04
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$128,8052-Wochen-Tief
$266,3852-Wochen-Hoch
Marktkapitalisierung (MRQ)
$15.30B
P/E (TTM)
16.1
EPS (TTM)
$14.63
Umsatz (TTM)
$4.60B
Ihre Abzeichen
52W-Spanne
$129–$266
Analystenbewertung
BUY
Kursziel
$294
P/E
16.1
ROE
22.1%
Nettogewinnmarge
20.4%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
JAZZ Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$236.04
Marktkapitalisierung (MRQ)
$15.30B
P/E (TTM)
16.1
EPS (TTM)
$14.63
Umsatz (TTM)
$4.60B
ROE (TTM)
22.1%
Verschuldungsgrad (MRQ)
0.9
52W-Spanne
$129–$266
JAZZ Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über Jazz Pharmaceuticals plc - Ordinary Shares Unternehmensübersicht von Wikipedia
Jazz Pharmaceuticals ist ein irisches biotechnologisches Pharmaunternehmen, das 2003 gegründet wurde und an der amerikanischen Technologiebörse NASDAQ unter dem Kennzeichen JAZZ gelistet ist. Seinen Hauptsitz hat Jazz Pharmaceuticals in Dublin, Irland. Das Unternehmen ist spezialisiert auf die Behandlung von Schlafstörungen und Epilepsie und erforscht und liefert in der Onkologie Medikamente für schwer zu behandelnde hämatologische Malignome und solide Tumore.
Medikamente
Jazz Pharmaceuticals hat u. a. folgende Medikamente im Markt:
Epidiolex (USA) / Epidyolex (EU) mit dem Wirkstoff Cannabidiol wird als Zusatztherapie von Krampfanfällen im Zusammenhang mit dem Lennox-Gastaut-Syndrom (LGS) oder dem Dravet-Syndrom (DS) in Verbindung mit Clobazam bei Patienten ab 2 Jahren angewendet.
Sativex (D, AT, CH) mit dem Wirkstoff Cannabis-Dickextrakt (mit eingestellten Gehalten an Tetrahydrocannabinol und Cannabidiol), wird angewendet zur Symptomverbesserung bei erwachsenen Patienten mit mittelschwerer bis schwerer Spastik aufgrund von Multipler Sklerose (MS), die nicht angemessen auf eine andere antispastische Arzneimitteltherapie angesprochen haben und die eine klinisch erhebliche Verbesserung von mit der Spastik verbundenen Symptomen während eines Anfangstherapieversuchs aufzeigen.
Xyrem (USA) mit dem Wirkstoff Natriumoxybat, zugelassen zur Behandlung von Narkolepsie mit Kataplexie bei Patienten ab einem Alter von 7 Jahren.
Xywave mit den Wirkstoffen Calcium-, Magnesium-, Kalium- und Natriumoxybat, zugelassen in den USA und Kanada zur Behandlung einer Kataplexie oder exzessiven Tagesschläfrigkeit (EDS) bei Patienten ab 7 Jahren mit Narkolepsie
Rylaze (USA) / Enrylaze (EU) mit dem Wirkstoff Crisantaspase zur Behandlung der akuten lymphatischen Leukämie (ALL) und des lymphoblastischen Lymphoms (LBL).
Geschichte
Jazz Pharmaceuticals wurde 2003 gegründet und wuchs primär durch den Zukauf von Produkten (z. B. Xyrem) und Zusammenschlüssen (Mergers) mit anderen Pharmaunternehmen (z. B. Azur Pharma, EUSA Pharma, Gentium, Celator etc.).
Im Mai 2021 gab Jazz Pharmaceuticals den Abschluss der Übernahme von GW Pharmaceuticals (Nasdaq: GWPH) bekannt, einem führenden Unternehmen in der Wissenschaft, Entwicklung und Vermarktung von verschreibungspflichtigen Medikamenten auf Cannabinoidbasis.
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BranchePharmaceuticals
Mitarbeiter2.890
LandIE
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$4.27B2016-12-31 → 2025-12-31
EPS$-5.842016-12-31 → 2025-12-31
Nettogewinnmarge20.4%
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | JAZZ | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | 16.15-Jahres-Durchschnitt ≈-12.5 | ≈-12.5 | · | · | |
| P/S (TTM) | 3.3 | · | · | · | |
| K/B (MRQ) | 3.2 | · | · | · | |
| Kurs / FCF (TTM) | 9.6 | · | · | · | |
| Kurs / Cashflow (TTM) | 9.2 | · | · | · | |
| Kurs / Materieller Buchwert (MRQ) | 19.8 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | JAZZ | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | 19.5% | · | · | · | |
| Vorgewinnmarge (TTM) | 15.8% | · | · | · | |
| Nettogewinnmarge (TTM) | 20.4% | · | · | · | |
| ROA (TTM) | 8.5% | · | · | · | |
| ROE (TTM) | 22.1% | · | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | JAZZ | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.9 | · | · | · | |
| Liquiditätsgrad (MRQ) | 1.8 | · | · | · | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.7 | · | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | JAZZ | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 4.9%5-Jahres-Durchschnitt ≈13.0% | ≈13.0% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 5.3%5-Jahres-Durchschnitt ≈10.8% | ≈10.8% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 12.5% | · | · | · | |
| EPS YoY (EPS VjV) | 41.8% | · | · | · | |
| Net Income YoY (Nettogewinn YoY) | 35.0% | · | · | · | |
| EPS CAGR 3Y (EPS CAGR 3J) | 13.1% | · | · | · | |
| Net Income CAGR 3Y (Nettoergebnis CAGR 3J) | 20.2% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | JAZZ | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$1.5M | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-1.6%
Nächster Bericht
Nov 03, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 3, 2026 | $5.71 | $6.30 | -9.4% |
| 31. März 2026 | $6.34 | $4.66 | 36.1% | |
| 31. Dezember 2025 | $6.64 | $6.65 | -0.11% | |
| 30. September 2025 | $8.13 | $6.04 | 34.7% | |
| 30. Juni 2025 | $-8.25 | $-7.76 | -6.4% | |
| 31. März 2025 | $1.68 | $4.75 | -64.6% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS (TTM) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | · | 60,696,000 | 61,200,000 | 61,000,000 | · | 61,414,000 | 62,882,000 | 62,537,000 | · | 63,114,000 | 63,991,000 | 63,494,000 | · | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | · | 61,606,000 | 61,200,000 | 61,000,000 | · | 63,174,000 | 69,625,000 | 62,537,000 | · | 71,293,000 | 73,540,000 | 73,771,000 | · | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $74.10 | $72.29 | · | $65.18 | $61.12 | $67.75 | · | $69.01 | $60.94 | $58.65 | · | $55.44 | · | · | · | · | |
| Revenue / Share | $17.41 | $16.17 | · | $18.28 | $17.09 | $14.72 | · | $16.70 | $14.70 | $14.42 | · | $13.64 | $13.02 | $12.10 | · | $14.98 | |
| Cash Flow / Share | · | $6.18 | · | · | · | $7.05 | · | · | · | $4.27 | · | · | · | $4.35 | · | · | |
| Cash / Share | $25.00 | $29.41 | · | $21.83 | $19.62 | $30.22 | · | $36.70 | $21.96 | $22.90 | · | $21.22 | · | · | · | · | |
| EPS (TTM) | $14.63 | $0.11 | · | $-6.21 | $-6.87 | $7.36 | · | $7.08 | $5.80 | $4.83 | · | $0.85 | $-1.60 | $-2.57 | · | $-0.37 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.60B | $4.44B | · | $4.16B | $4.09B | $4.06B | · | $3.99B | $3.91B | $3.84B | · | $3.79B | $3.76B | $3.74B | · | $3.58B | |
| Net Income TTM | $941M | $29M | · | $-368M | $-405M | $482M | · | $463M | $395M | $331M | · | $80M | $-87M | $-156M | · | $-19M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | 16.5 | 1718.6 | · | -21.2 | -15.4 | 16.9 | · | 15.7 | 18.4 | 24.9 | · | 152.3 | -77.5 | -56.9 | · | -360.2 | |
| P/S | 3.4 | 2.7 | · | 1.9 | 1.6 | 1.9 | · | 1.7 | 1.7 | 2.0 | · | 2.1 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| EV / Revenue | 4.0 | 3.5 | · | 2.9 | 2.6 | 2.7 | · | 2.7 | 2.8 | 3.1 | · | 3.3 | · | · | · | · | |
| Earnings Yield | 6.1% | 0.06% | · | -4.7% | -6.5% | 5.9% | · | 6.3% | 5.4% | 4.0% | · | 0.66% | -1.3% | -1.8% | · | -0.28% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Nettoergebnis | $-356M | $560M | $415M | $-224M | $-330M |
| Verwässerte EPS | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Keine Daten für diese Aufstellung
Noch nicht genügend Fundamentaldaten vorhanden, um diese Aufstellung zu erstellen.
Keine Daten für diese Aufstellung
Noch nicht genügend Fundamentaldaten vorhanden, um diese Aufstellung zu erstellen.
Institutionelle Eigentümer (13F) 687 Einreicher · $15.8B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
687
Gehaltener Wert
$15.8B
Neue Positionen
138
Geschlossene Positionen
56
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 138 (+32 vs. Vorquartal) | 56 (-21 vs. Vorquartal) | 240 (+24 vs. Vorquartal) | 188 (+19 vs. Vorquartal) | +942K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $1.438.254.453 | 5.968.603 | 9,11% | Aktien |
| FMR LLC | $1.110.709.035 | 4.609.326 | 7,04% | Aktien |
| VANGUARD GROUP INC | $1.005.914.140 | 5.917.142 | 6,37% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731.636.247 | 3.036.213 | 4,64% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $657.763.761 | 2.729.650 | 4,17% | Aktien |
| Capital World Investors | $650.043.082 | 2.697.610 | 4,12% | Aktien |
| FRANKLIN RESOURCES INC | $491.639.148 | 2.040.250 | 3,12% | Aktien |
| STATE STREET CORP | $481.895.662 | 1.999.816 | 3,05% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $412.909.300 | 1.713.592 | 2,62% | Aktien |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394.839.917 | 1.638.544 | 2,50% | Aktien |
| Bank of New York Mellon Corp | $380.253.849 | 1.578.013 | 2,41% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $359.935.093 | 1.522.568 | 2,28% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $357.440.125 | 1.483.031 | 2,26% | Aktien |
| AMERIPRISE FINANCIAL INC | $292.895.571 | 1.215.523 | 1,86% | Aktien |
| JPMORGAN CHASE & CO | $276.634.191 | 1.160.786 | 1,75% | Aktien |
| BANK OF AMERICA CORP /DE/ | $273.763.940 | 1.136.091 | 1,73% | Aktien |
| CITADEL ADVISORS LLC | $242.578.716 | 1.006.676 | 1,54% | Aktien |
| Swedbank AB | $233.281.128 | 968.092 | 1,48% | Aktien |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $192.606.598 | 799.297 | 1,22% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $184.072.164 | 763.880 | 1,17% | Aktien |
| UBS Group AG | $182.381.760 | 756.865 | 1,16% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $165.478.678 | 686.719 | 1,05% | Aktien |
| NORGES BANK | $158.279.458 | 656.843 | 1,00% | Aktien |
| MORGAN STANLEY | $151.734.512 | 629.680 | 0,96% | Aktien |
| Mariner, LLC | $146.630.968 | 608.615 | 0,93% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $135.442.731 | 562.073 | 0,86% | Aktien |
| Allianz Asset Management GmbH | $131.345.759 | 545.071 | 0,83% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129.891.746 | 539.037 | 0,82% | Aktien |
| NORTHERN TRUST CORP | $123.222.660 | 511.361 | 0,78% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $111.450.794 | 462.509 | 0,71% | Aktien |
| GMT Capital Corp | $109.279.895 | 453.500 | 0,69% | Aktien |
| Boston Trust Walden Corp | $106.779.349 | 443.123 | 0,68% | Aktien |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105.278.106 | 436.893 | 0,67% | Aktien |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103.893.734 | 431.148 | 0,66% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $96.439.086 | 400.212 | 0,61% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $95.008.929 | 394.277 | 0,60% | Aktien |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $91.259.201 | 378.715 | 0,58% | Aktien |
| Nuveen, LLC | $88.051.524 | 365.405 | 0,56% | Aktien |
| Sofinnova Investments, Inc. | $88.036.221 | 365.341 | 0,56% | Aktien |
| Polaris Capital Management, LLC | $79.270.937 | 328.966 | 0,50% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $77.695.234 | 322.427 | 0,49% | Aktien |
| GOLDENTREE ASSET MANAGEMENT LP | $70.838.675 | 294.435 | 0,45% | Aktien |
| Qube Research & Technologies Ltd | $70.056.003 | 290.725 | 0,44% | Aktien |
| GOLDMAN SACHS GROUP INC | $67.434.009 | 279.844 | 0,43% | Aktien |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66.815.854 | 277.279 | 0,42% | Aktien |
| Quantinno Capital Management LP | $65.906.960 | 273.506 | 0,42% | Aktien |
| BANK OF MONTREAL /CAN/ | $58.329.921 | 242.063 | 0,37% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $55.096.752 | 228.645 | 0,35% | Aktien |
| Tri Locum Partners LP | $53.427.868 | 221.720 | 0,34% | Aktien |
| Invesco Ltd. | $50.427.310 | 209.268 | 0,32% | Aktien |
Aktivisten & 5%+-Eigentümer 6 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 Einreichungen | 20. Juni 2014 | · | Erste Einreichung | · | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 Einreichungen | 12. März 2013 | · | Erste Einreichung | · | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 Einreichungen | 14. März 2012 | · | Erste Einreichung | Kapitalstruktur | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 Einreichungen | 30. September 2011 | · | Erste Einreichung | · | SEC |
| Azur Pharma Limited | 28. September 2011 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | 28. April 2005 | · | Erste Einreichung | M&A / Verkauf | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 56 Insider · 18 Führungskräfte · 20 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | 8. September 2026 S | 143.394 | 0 | 1 | $-486.060 |
| Philip L Johnson | EVP & Chief Financial Officer | 30. Juni 2026 F | 56.431 | 0 | 0 | $0 |
| Matthew P. Young | EVP & CFO | 6. März 2019 S | 36.200 | 0 | 0 | $0 |
| Daniel N Swisher JR | President and COO | 5. März 2023 F | 55.014 | 0 | 0 | $0 |
| Christopher J. Tovey | EVP, COO & Managing Director E | 5. Juli 2022 M | 14.663 | 0 | 0 | $0 |
| Russell J. Cox | EVP & COO | 11. Dezember 2017 M | 102.821 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | 10. September 2026 S | 47.671 | 0 | 14 | $-11.500.359 |
| Mary Elizabeth Henderson | SVP, Technical Operations | 8. September 2026 F | 23.815 | 0 | 2 | $-1.418.523 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 27. August 2026 M | 65.686 | 0 | 7 | $-20.411.738 |
| Samantha Pearce | EVP, Chief Commercial Officer | 5. August 2026 F | 47.131 | 0 | 1 | $-1.625.977 |
| Patricia Carr | SVP, Chief Accounting Officer | 9. März 2026 S | 6.512 | 0 | 7 | $-2.458.091 |
| Kim Sablich | EVP, GM of U.S. | 5. Juni 2023 D | 28.478 | 0 | 0 | $0 |
| Finbar Larkin | SVP, Technical Operations | 6. März 2023 M | 21.779 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | EVP, US Commercial | 12. März 2020 S | 22.118 | 0 | 0 | $0 |
| Paul Treacy | SVP, Technical Operations | 12. August 2019 S | 16.418 | 0 | 0 | $0 |
| Iain Mcgill | SVP, Europe & Rest of World | 5. März 2019 F | 24.938 | 0 | 0 | $0 |
| Karen J Wilson | SVP, Finance & PAO | 5. März 2019 F | 18.385 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | EVP & General Counsel | 27. Februar 2019 M | 39.738 | 0 | 0 | $0 |
| Bruce C Cozadd | Direktor | 1. September 2026 S | 351.875 | 0 | 19 | $-26.393.546 |
| Patrick Kennedy | Direktor | 31. August 2026 F | 6.452 | 0 | 0 | $0 |
| Mark Douglas Smith | Direktor | 31. August 2026 F | 9.579 | 0 | 1 | $-266.746 |
| Jennifer E. Cook | Direktor | 31. August 2026 F | 10.736 | 0 | 0 | $0 |
| Laura Hamill | Direktor | 31. August 2026 F | 6.832 | 0 | 0 | $0 |
| Heather Ann Mcsharry | Direktor | 31. August 2026 F | 18.199 | 0 | 2 | $-1.089.119 |
| Rick E Winningham | Direktor | 31. August 2026 F | 9.466 | 0 | 2 | $-1.656.873 |
| Patrick G. Enright | Direktor | 31. August 2026 F | 21.278 | 0 | 0 | $0 |
| Ted W Love | Direktor | 31. August 2026 F | 2.389 | 0 | 0 | $0 |
| Norbert G Riedel | Direktor | 31. August 2026 F | 6.923 | 0 | 1 | $-655.680 |
| Seamus Mulligan | Direktor | 5. August 2026 A | 1.184.633 | 0 | 0 | $0 |
| Anne Oriordan | Direktor | 8. August 2025 F | 16.500 | 0 | 0 | $0 |
| Peter Gray | Direktor | 14. August 2023 S | 16.068 | 0 | 0 | $0 |
| Catherine A. Sohn | Direktor | 14. August 2023 S | 14.868 | 0 | 0 | $0 |
| Elmar Schnee | Direktor | 5. August 2021 S | 8.270 | 0 | 0 | $0 |
| Paul L Berns | Direktor | 5. August 2021 S | 8.290 | 0 | 0 | $0 |
| Bryan C Cressey | Direktor | 9. März 2012 S | 27.631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | Direktor | 10. März 2011 A | · | 0 | 0 | $0 |
| Alexander E Albert | Direktor | 15. August 2008 A | · | 0 | 0 | $0 |
| Patel Jaimin | Direktor | 15. August 2007 A | · | 0 | 0 | $0 |
| Kenneth W O'Keefe | · | 2. Dezember 2025 F | 25.811 | 0 | 0 | $0 |
| Karen L. Smith | · | 5. März 2018 F | 28.474 | 0 | 0 | $0 |
| Jeffrey K Tobias | · | 5. März 2015 F | 38.484 | 0 | 0 | $0 |
| Fintan Keegan | · | 8. Juli 2014 M | 31.750 | 0 | 0 | $0 |
| Kathryn E Falberg | · | 5. März 2014 F | 133.387 | 0 | 0 | $0 |
| James C Momtazee | · | 13. August 2013 S | 17.315 | 0 | 0 | $0 |
| Carol A Gamble | · | 9. März 2012 S | 32.213 | 0 | 0 | $0 |
| Alan Sebulsky | · | 9. März 2012 S | 54.355 | 0 | 0 | $0 |
| Samuel D Colella | · | 11. Januar 2012 M | 38.347 | 0 | 0 | $0 |
| Michael W Michelson | · | 11. Januar 2012 M | 13.885 | 0 | 0 | $0 |
| Mark G. Eller | · | 13. August 2011 M | 4.151 | 0 | 0 | $0 |
| Michael A. Desjardin | · | 13. August 2011 M | 14.574 | 0 | 0 | $0 |
| Janne Lt Wissel | · | 31. Mai 2011 J | 48.544 | 0 | 0 | $0 |
| Joan Colligan | · | 30. November 2010 J | 14.424 | 0 | 0 | $0 |
| Robert M Myers | · | 30. November 2010 J | 156.898 | 0 | 0 | $0 |
| James B Tananbaum | · | 25. August 2010 A | 21.366 | 0 | 0 | $0 |
| Samuel R Saks | · | 21. Januar 2009 A | 358.868 | 0 | 0 | $0 |
| Matthew K Fust | · | 28. November 2008 J | 58.948 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 61 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IHE · iShares Trust | 3,45% | 232.236 SH | 11. September 2026 | Täglich |
| PJP · Invesco Exchange-Traded Fund Trust | 2,92% | 68.707 SH | 2. Oktober 2026 | Täglich |
| XMMO · Invesco Exchange-Traded Fund Trust | 2,29% | 699.736 SH | 2. Oktober 2026 | Täglich |
| PILL · Direxion Shares ETF Trust | 1,25% | 1.023 NS | 31. Juli 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,01% | 4.592 SH | 2. Oktober 2026 | Täglich |
| RFG · Invesco Exchange-Traded Fund Trust | 0,96% | 13.808 SH | 2. Oktober 2026 | Täglich |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,79% | 61.910 SH | 19. August 2026 | Täglich |
| PDP · Invesco Exchange-Traded Fund Trust | 0,64% | 40.761 SH | 2. Oktober 2026 | Täglich |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,58% | 14.802 NS | 31. Juli 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,54% | 27.352 NS | 31. Juli 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,49% | 8.679 SH | 2. Oktober 2026 | Täglich |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,41% | 101.353 SH | 19. August 2026 | Täglich |
| MIDU · Direxion Shares ETF Trust | 0,34% | 921 NS | 31. Juli 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,32% | 11.363 SH | 19. August 2026 | Täglich |
| VBR · VANGUARD INDEX FUNDS | 0,31% | 867.777 SH | 19. August 2026 | Täglich |
| VFMF · VANGUARD WELLINGTON FUND | 0,28% | 8.083 SH | 19. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,28% | 168.574 NS | 31. Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,24% | 19.561 SH | 19. August 2026 | Täglich |
| IYH · iShares Trust | 0,23% | 34.871 SH | 11. September 2026 | Täglich |
| ESML · iShares Trust | 0,22% | 25.740 SH | 11. September 2026 | Täglich |
| DFAT · Dimensional ETF Trust | 0,22% | 123.193 NS | 31. Juli 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,20% | 166.548 SH | 19. August 2026 | Täglich |
| SMMD · iShares Trust | 0,20% | 31.945 SH | 11. September 2026 | Täglich |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,18% | 9.978 SH | 2. Oktober 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,17% | 719.903 SH | 19. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,17% | 1.366.973 SH | 19. August 2026 | Täglich |
| IWS · iShares Trust | 0,14% | 88.598 SH | 11. September 2026 | Täglich |
| WSML · iShares Trust | 0,13% | 3.647 SH | 11. September 2026 | Täglich |
| IWR · iShares Trust | 0,11% | 244.305 SH | 11. September 2026 | Täglich |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 3.144 SH | 2. Oktober 2026 | Täglich |
| XT · iShares Trust | 0,09% | 13.710 SH | 11. September 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,08% | 147.012 NS | 31. Juli 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,08% | 45.748 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,05% | 7.084 NS | 31. Juli 2026 | N-PORT |
| IUSG · iShares Trust | 0,04% | 55.258 SH | 11. September 2026 | Täglich |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,04% | 36.014 SH | 19. August 2026 | Täglich |
| IWD · iShares Trust | 0,04% | 133.301 SH | 11. September 2026 | Täglich |
| DSI · iShares Trust | 0,04% | 8.411 SH | 11. September 2026 | Täglich |
| PRF · Invesco Exchange-Traded Fund Trust | 0,04% | 15.040 SH | 2. Oktober 2026 | Täglich |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 1.371 SH | 2. Oktober 2026 | Täglich |
| DFAU · Dimensional ETF Trust | 0,03% | 13.729 NS | 31. Juli 2026 | N-PORT |
| DYNF · BlackRock ETF Trust | 0,02% | 39.438 SH | 11. September 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,02% | 467 NS | 31. Juli 2026 | N-PORT |
| IYY · iShares Trust | 0,02% | 2.648 SH | 11. September 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,02% | 17.349 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,02% | 81.293 SH | 11. September 2026 | Täglich |
| IWB · iShares Trust | 0,02% | 41.012 SH | 11. September 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 1.892.855 SH | 19. August 2026 | Täglich |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 9.995 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 5.021 SH | 19. August 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,02% | 13.490 SH | 19. August 2026 | Täglich |
| IWV · iShares Trust | 0,02% | 16.075 SH | 10. September 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 49.429 SH | 19. August 2026 | Täglich |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1.238 SH | 2. Oktober 2026 | Täglich |
| NEAR · iShares U.S. ETF Trust | 0,00% | 200.000 SH | 9. September 2026 | Täglich |
| IJH · iShares Trust | · | 2.201.423 SH | 11. September 2026 | Täglich |
| IJK · iShares Trust | · | 363.871 SH | 11. September 2026 | Täglich |
| XJH · iShares Trust | · | 8.572 SH | 8. September 2026 | Täglich |
| ISCB · iShares Trust | · | 2.820 SH | 11. September 2026 | Täglich |
| ISCV · iShares Trust | · | 13.894 SH | 11. September 2026 | Täglich |
| SMMV · iShares Trust | · | 4.635 SH | 19. August 2026 | Täglich |
JAZZ Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 26 Analysten
KAUF
Median-Ziel
$300.00
+27,1%
7 26,9%
Starker Kauf
17 65,4%
Kauf
2 7,7%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
22 Analysten · 2026-10-03Mittelwert-Ziel $294.27 +24,7%
Jetzt
Aktueller Preis $236.04
Tief$225.00
Mittelwert$294.27
Hoch$337.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 3, 2026